Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)
Ian D. Pavord1, Flavia C.L. Hoyte2, Andrew W. Lindsley3, Christopher S. Ambrose4, Joseph D. Spahn5, Stephanie L. Roseti6, Bill Cook4, Janet M. Griffiths7, Åsa Hellqvist8, Nicole Martin9,10, Jean-Pierre Llanos11, Neil Martin12,13, Gene Colice6, Jonathan Corren14
1Respiratory Medicine, NIHR Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
2Division of Allergy and Immunology, National Jewish Health, Denver, Colorado
3US Medical Affairs, Amgen, Thousand Oaks, California
4Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland
5Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware
6Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland
7Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland
8Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
9Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts
10Cytel Inc., Waltham, Massachusetts
11Global Medical Affairs, Amgen, Thousand Oaks, California
12Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
13NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom
14David Geffen School of Medicine, University of California, Los Angeles, California
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Annals of Allergy, Asthma & Immunology
Tập 131
587-597.e3
Thông tin tác giả